2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
Avatar

2020 ASCO Update on HR+ BC: Is There a Prognostic Utility of MammaPrint for CT Untreated C-High/G-Low Risk Women After 8.7 Years?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Reshma L. Mahtani
By 2020 ASCO Virtual Direct™ Highlights FEATURING Reshma L. Mahtani
86 views
August 19, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

19:51
AstraZeneca Oncology

Management Strategies for Fatigue and Asthenia in First-line Mainten…

Feat. D. Czel, C. Arn
Breast
11:09
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HER2+ mBC: Does T-DXd Dosage Change How Effe…

Feat. A. Elias
07:38
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on mBC: What Are the Response Rates With Olaparib?…

Feat. A. Elias
06:45
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on 1L mTNBC: Does Pembro+Chemo Improve PFS vs. Che…

Feat. A. Elias
07:23
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ BC: Fulvestrant / Fulvestrant + Anastrozole …

Feat. R. L. Mahtani
06:29
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ BC: Is There a Prognostic Utility of MammaPr…

Feat. R. L. Mahtani
09:38
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ BC: Does Replacing Adjuvant Taxane & T…

Feat. R. L. Mahtani
08:28
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on BC: Does Maintenance Therapy With Metronomic Cap…

Feat. R. L. Mahtani